| Author | Year | Type | Assay | Amounts (T/C) | Country | Treatment group | Threshold | TP | FP | FN | TN |
| CUICL [8] | 2023 | serum | ELISA | 180 (90/90) | China | NSCLC | 64.61 ng/mL | 70 | 23 | 20 | 67 |
| FANW [9] | 2023 | serum | ELISA | 93 (61/32) | China | NSCLC | 101.99 ng/mL | 46 | 8 | 15 | 24 |
| YUANZ [10] | 2022 | plasma | ELISA | 335 (175/160) | China | LC | 50.02 ng/mL | 154 | 49 | 21 | 111 |
| DONGXY [11] | 2022 | plasma | ELISA | 175 (109/66) | China | LC | 82.06 ng/mL | 87 | 2 | 22 | 64 |
| CHENYJ [12] | 2022 | serum | ELISA | 400 (232/168) | China | LC | 121.41 ng/mL | 170 | 40 | 62 | 128 |
| ZHOUW [13] | 2021 | plasma | ELISA | 118 (78/40) | China | LC | 82.06 ng/mL | 73 | 15 | 5 | 25 |
| WANGY [14] | 2021 | plasma | ELISA | 472 (312/160) | China | LC | 71.47 ng/mL | 207 | 8 | 105 | 152 |
| WANGX [15] | 2020 | plasma | ELISA | 148 (118/30) | China | LC | 75.08 ng/mL | 85 | 4 | 33 | 26 |
| GAOM [16] | 2020 | serum | ELISA | 124 (62/62) | China | LC | 64.61 ng/mL | 48 | 31 | 14 | 31 |
| ZHANGCH [17] | 2019 | plasma | ELISA | 108 (58/50) | China | LC | 82.06 ng/mL | 49 | 5 | 9 | 45 |
| JIANGY [18] | 2018 | plasma | ELISA | 144 (87/57) | China | LC | 61.37 ng/mL | 81 | 21 | 6 | 36 |
| ZHANGMC [19] | 2018 | serum | ELISA | 133 (87/46) | China | LC | 90.95 ng/mL | 57 | 4 | 30 | 42 |
| DONGL [20] | 2017 | serum | ELISA | 186 (166/20) | China | LC | 88.4 ng/mL | 122 | 1 | 44 | 19 |
| SUNY [21] | 2017 | plasma | ELISA | 114 (94/20) | China | LC | 82 ng/mL | 40 | 1 | 54 | 19 |
| JIANGQ [22] | 2016 | plasma | ELISA | 84 (60/24) | China | LC | 82.06 ng/mL | 50 | 10 | 2 | 22 |
| ZHANGS [23] | 2015 | serum | ELISA | 100 (50/50) | China | NSCLC | 369.26 pg/mL | 23 | 15 | 27 | 35 |
| ZHANGS [24] | 2015 | serum | ELISA | 150 (100/50) | China | NSCLC | 350.12 pg/mL | 47 | 19 | 53 | 31 |
| SHIY [25] | 2014 | plasma | ELISA | 1638 (1046/592) | China | LC | 56.33 ng/mL | 755 | 126 | 291 | 466 |